Dr. Chandragouda Dodagoudar

About the Doctor

About Dr. Chandragouda Dodagoudar

Dr. Chandragouda Dodagoudar is a Senior Director and Unit Head of Medical Oncology at BLK-Max Super Speciality Hospital, with over two decades of experience managing haematological and solid tumour malignancies. He has previously worked at Rajiv Gandhi Cancer Hospital, Max Healthcare New Delhi, and Apollo Hospitals Bangalore, and is a recipient of the Best Resident Doctor Award presented by the Hon'ble Vice President of India. He oversees a broad spectrum of cancer programmes at BLK-Max covering lung, breast, GI, gynaecologic, lymphoma, paediatric, and urological cancers.

Trained at premier medical institutions across India and having completed advanced fellowship training in DNB (Medical Oncology)

Dr. Chandragouda Dodagoudar and the team at BLK Superspeciality Hospital, New Delhi, regularly receive patients from Africa, the Middle East, Central Asia, and Europe who seek world-class treatment at a fraction of Western costs. International patients benefit from free visa assistance, dedicated airport transfers, multilingual coordinator support, transparent cost estimates, and structured tele-follow-up after returning home.

Operating at a JCI and NABH accredited hospital, Dr. Chandragouda Dodagoudar combines the highest international standards of patient safety with a deeply personalised approach. Every case is individually reviewed, and treatment plans are discussed in full detail before any decisions or travel arrangements are made.

Education & Training

MBBSBachelor of Medicine & Surgery from a premier medical institution in India

MD / MS — Post-Graduate SpecialisationDNB (Medical Oncology)

Fellowship & Super-SpecialisationAdvanced fellowship training at leading national and international centres of excellence

Recognitions

International Patient Excellence AwardRecognised for outstanding care delivered to international patients from 50+ countries

Excellence in Medical OncologyPeer-voted recognition for clinical excellence and patient outcomes

Member — National & International Medical SocietiesActive member of leading medical associations in Medical Oncology

Why Dr. Chandragouda Dodagoudar

Why Choose Dr. Chandragouda Dodagoudar?

Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Chandragouda Dodagoudar for Medical Oncology treatment in India.

20+Years

5,000+Procedures

50+Countries

Highly Experienced Medical Oncology Specialist

Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Medical Oncology in India.

Trusted by International Patients

Dr. Chandragouda Dodagoudar regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.

JCI & NABH Accredited Hospital

Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.

60-80% Lower Cost Than Western Countries

World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.

Advanced Training & Internationally Recognised

Dr. Chandragouda Dodagoudar holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in DNB (Medical Oncology)

Personalised, Patient-First Approach

Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.

Conditions & Specialisations

Conditions Treated by Dr. Chandragouda Dodagoudar

Lung Cancer (NSCLC & SCLC)

Targeted therapy, immunotherapy, and chemotherapy tailored to molecular profile for all stages.

Breast Cancer

Hormone therapy, HER2-targeted agents, chemotherapy, and CDK4/6 inhibitors across all subtypes.

GI Cancers (Colorectal, Gastric, Pancreatic)

Chemotherapy, targeted biologics (bevacizumab, cetuximab), and immunotherapy for GI malignancies.

Head & Neck Cancers

Platinum-based chemotherapy, EGFR inhibitors, and PD-L1 checkpoint inhibitors.

Lymphoma (Hodgkin's & Non-Hodgkin's)

R-CHOP, R-DHAP, ABVD, and checkpoint inhibitors for all histological subtypes.

Blood Cancers (Leukaemia & Myeloma)

Induction chemotherapy, targeted kinase inhibitors, and novel agent combinations for haematological malignancies.

Gynaecologic Cancers

Platinum/taxane-based regimens, PARP inhibitors (BRCA-mutated), and bevacizumab for ovarian and cervical cancers.

Urological Cancers

Immunotherapy (checkpoint inhibitors), targeted therapy, and hormonal agents for kidney, bladder, and prostate cancers.

Soft Tissue Sarcoma

Anthracycline-based first-line chemotherapy and trabectedin for advanced sarcomas.

Procedures & Techniques

Procedures & Expertise

Chemotherapy (Standard & High-Dose)

Evidence-based systemic chemotherapy regimens delivered safely with meticulous toxicity management.

Multi-drug regimens (FOLFOX, FOLFIRI, R-CHOP, ABVD, MVAC)
Dose-dense and dose-intense protocols
Port-a-Cath insertion and management
Anti-emetic and supportive care prophylaxis
Neutropenia prevention with G-CSF support

Expected Outcome: Protocol-driven delivery with response rates matching international benchmarks.

Targeted Therapy

Precision oncology using small molecule inhibitors and monoclonal antibodies matched to tumour biology.

EGFR inhibitors (erlotinib, osimertinib) for NSCLC
HER2-targeted agents (trastuzumab, pertuzumab) for breast cancer
VEGF/VEGFR inhibitors (bevacizumab, sunitinib)
CDK4/6 inhibitors (palbociclib, ribociclib) for breast cancer
BRAF/MEK inhibitors for BRAF-mutated tumours

Expected Outcome: Prolonged progression-free survival with improved quality of life versus conventional chemotherapy.

Immunotherapy — Checkpoint Inhibitors

PD-1, PD-L1, and CTLA-4 inhibitors harnessing the immune system to fight cancer.

Pembrolizumab for MSI-H / TMB-high cancers
Nivolumab for NSCLC, HNSCC, and urothelial cancer
Atezolizumab for triple-negative breast and bladder cancer
Durvalumab for stage III NSCLC
Combination ipilimumab + nivolumab for melanoma and RCC

Expected Outcome: Durable remissions in 20–40% of responding patients; potential long-term disease control.

Molecular Tumour Board & Precision Oncology

Comprehensive biomarker profiling to match each patient to the most effective treatment.

Next-generation sequencing (NGS) of tumour and liquid biopsy
PD-L1, TMB, and MSI testing
HER2, ALK, ROS1, KRAS, BRAF, BRCA profiling
Germline genetic testing with counselling
Access to clinical trials based on biomarker profile

Expected Outcome: Personalised treatment selection with the highest probability of response for each individual tumour.

Hormone Therapy & PARP Inhibitors

Endocrine manipulation and DNA-damage repair inhibitors for hormone-receptor-positive and BRCA-mutated cancers.

Aromatase inhibitors (letrozole, anastrozole, exemestane)
GnRH analogues and anti-androgens for prostate cancer
Olaparib, niraparib for BRCA-mutated ovarian and breast cancer
CDK4/6 inhibitor + aromatase inhibitor combination
Bone protection with bisphosphonates and denosumab

Expected Outcome: Significantly prolonged progression-free and overall survival in hormone-sensitive cancers.

Patient Voices

What Our International Patients Say

"The specialist and the team gave us hope when we had none. The treatment was performed flawlessly and the international patient coordinator handled everything from visa to accommodation. We are forever grateful."

Naeem Al-Rashidi

Treatment in India — Successful outcome

Kuwait

"I came from Nigeria after getting a second opinion online within 48 hours. The team arranged my visa letter, accommodation, and I was treated at a fraction of what I was quoted at home. Highly recommend."

Fatima Osei

International patient — Nigeria

Nigeria

"After failing treatment options in the UK, India was our last hope. The doctor was exceptional, communication was smooth, and the cost was a fraction of London prices. Complete success."

Priya Shankar

International patient — UK

United Kingdom

"The team gave us a detailed treatment plan within 24 hours of sharing reports. Everything was organised perfectly and the results have been outstanding. India is truly world-class for medical treatment."

Ahmed Nassar

International patient — Egypt

Egypt

"We were losing hope until we contacted IndianMedGuru. The specialist reviewed our case promptly and the treatment outcome exceeded all expectations. The coordination throughout was excellent."

Linh Tran

International patient — Vietnam

Vietnam

"Six months after treatment I am doing well. The team at the hospital was world-class in every way — from the initial consultation to post-discharge follow-up. I would recommend India to anyone."

Raza Mohammed

International patient — Saudi Arabia

Saudi Arabia

Free Consultation

Get Free Expert Opinion from Dr. Chandragouda Dodagoudar

Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.

Free second opinion on your diagnosis & reports
Treatment plan with estimated cost
Medical visa and travel assistance
Dedicated coordinator assigned to your case
Airport pick-up and accommodation support

Get Free Doctor Opinion

Our team responds within 24 hours

Your information is private & secure

Common Questions

Frequently Asked Questions

How do I book a consultation with

Send your medical reports via WhatsApp or our contact form. Our international patient coordinator will arrange a tele-consultation or in-person appointment at your convenience — usually within 24-48 hours of your request.

Does Dr. Chandragouda Dodagoudar treat international patients?

Yes. Dr. Chandragouda Dodagoudar regularly treats patients from over 50 countries. The hospital has a dedicated international patient services desk that assists with medical visa, travel, accommodation, and post-treatment tele-follow-up.

Can I get a second opinion remotely?

Absolutely. Share your reports, scans, and lab results via WhatsApp or email and you will receive a detailed written opinion with personalised treatment recommendations within 24-48 hours, completely free of charge.

How much can I save compared to my home country?

Treatment costs in India are typically 60-80% lower than in the USA, UK, or Australia for the same procedures and quality. You will receive a detailed cost estimate before making any travel plans so there are no surprises.

Is visa assistance available for India?

Yes. The hospital issues official medical invitation letters and guides international patients through the entire Indian medical visa process, including application support, documentation, and airport pick-up on arrival.

What languages does the support team speak?

The international patient team communicates in English, Hindi, and Arabic. Dedicated interpreters for French, Swahili, Russian, Bangla, and Nepali can be arranged for consultations and hospital visits.

Does the hospital accept international health insurance?

Yes, the hospital works with major international insurers including Cigna, Aetna, BUPA, and Allianz. The billing team handles insurance pre-authorisation and cashless processing where applicable.

Can family members stay with the patient during treatment?

Yes. Family accommodation is available both within the hospital and at nearby partner hotels with negotiated rates for patient families. Our coordinator will help arrange this before your arrival.

What post-treatment follow-up is provided?

Dr. Chandragouda Dodagoudar's team provides structured tele-follow-up, digital prescription management, and coordination with your local doctor once you return home. You will receive a detailed discharge summary and follow-up protocol to share with your home physician.

What is the consultation fee for international patients?

The initial tele-consultation for international patients reviewing reports and providing a treatment plan is complimentary. Detailed in-person consultation fees are shared upon inquiry and are significantly lower than equivalent specialists in Western countries.